High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours
- 31 December 1993
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 29 (11) , 1504-1509
- https://doi.org/10.1016/0959-8049(93)90283-l
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- POMBACE chemotherapy in non-seminomatous germ cell tumours: Outcome and importance of dose intensityEuropean Journal Of Cancer, 1992
- Clinical Pharmacokinetics of CarboplatinClinical Pharmacokinetics, 1991
- Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.Journal of Clinical Oncology, 1991
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989
- Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol.Journal of Clinical Oncology, 1989
- A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.Journal of Clinical Oncology, 1988
- Prognostic factors in advanced nonseminomatous testicular cancer a multivariate logistic regression analysisCancer, 1988
- Carboplatin: current status and future prospectsCancer Treatment Reviews, 1988
- Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or EtoposideNew England Journal of Medicine, 1987
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976